Time to Decision and Treatment With tPA (Tissue-Type Plasminogen Activator) Using Telemedicine Versus an Onboard Neurologist on a Mobile Stroke Unit | Zendy

Ritvij Bowry | Zendy; Stephanie Parker | Zendy; JoséMiguel Yamal | Zendy; Hyunsoo Hwang | Zendy; Savitri Appana | Zendy; Nicole Rangel-Gutierrez | Zendy; TzuChing Wu | Zendy; Suja S. Rajan | Zendy; James C. Grotta | Zendy

Open Access

Time to Decision and Treatment With tPA (Tissue-Type Plasminogen Activator) Using Telemedicine Versus an Onboard Neurologist on a Mobile Stroke Unit

Author(s) -

Ritvij Bowry,

Stephanie Parker,

JoséMiguel Yamal,

Hyunsoo Hwang,

Savitri Appana,

Nicole Rangel-Gutierrez,

TzuChing Wu,

Suja S. Rajan,

James C. Grotta

Publication year - 2018

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.117.020585

Subject(s) - interquartile range , medicine , thrombolysis , tissue plasminogen activator , bolus (digestion) , telemedicine , stroke (engine) , fibrinolytic agent , plasminogen activator , emergency medicine , mechanical engineering , health care , myocardial infarction , engineering , economics , economic growth

Mobile stroke units (MSUs) can speed treatment with intravenous tPA (tissue-type plasminogen activator). We previously showed substantial agreement between a telemedicine-based vascular neurologist (TM-VN) and an onboard vascular neurologist (OB-VN) for the evaluation of patients with stroke for tPA eligibility on an MSU. However, the time efficiency of the telemedicine-based evaluation remained uncertain. In this study, we examined the speed of decision and treatment from MSU arrival for the TM-VN compared with an OB-VN.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research